Irvine, California, USA, November 8, 2026
Allergan Aesthetics, an AbbVie company, has announced encouraging clinical findings from two Phase 4 studies evaluating aesthetic treatments in adults taking glucagon-like peptide-1 (GLP-1) medications for weight management. The studies, known as HARMONY IN DIVERSITY and HALO, demonstrated improvements in patient satisfaction with facial appearance, skin quality and perceptions of natural-looking results following aesthetic treatments. The findings were presented at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting, held from November 5–8 in San Diego, California. GLP-1 medications are increasingly used to support weight management and metabolic health. However, significant weight loss can also lead to visible facial changes, including reduced facial volume and alterations in skin appearance. These changes may influence an individual’s confidence, self-image and satisfaction with their appearance. To better understand these concerns, Allergan Aesthetics evaluated different aesthetic treatment approaches specifically in adults taking stable doses of GLP-1 medications. The research provides additional clinical evidence about multimodal aesthetic treatments and patient-reported outcomes in this growing population.
HARMONY IN DIVERSITY Demonstrates Significant Improvements
The HARMONY IN DIVERSITY study evaluated a multimodal aesthetic treatment approach combining hyaluronic acid (HA) injectable fillers, onabotulinumtoxinA and a study-specified skincare regimen. The GLP-1 medical weight loss cohort included 30 adults who received the combined treatment approach. Researchers assessed treatment outcomes using validated patient-reported measures, including the FACE-Q Satisfaction With Facial Appearance questionnaire. Results demonstrated a statistically significant mean improvement of 42.4 points in facial appearance satisfaction from baseline to 30 days following onabotulinumtoxinA treatment. Participants also reported statistically significant improvements in skin quality, psychological function and social function. These findings suggest that combining injectable treatments with skincare may address multiple aesthetic concerns associated with medical weight loss. The safety observations were also encouraging, with most treatment-related adverse events reported as mild, nonserious and resolving without intervention. Additionally, researchers reported no evidence of distant toxin spread. The study represents an important investigation because it evaluates the combined use of neurotoxin and dermal filler treatments in adults receiving GLP-1 medications.
HALO Study Reports High Patient Satisfaction With HA Injectables
The second investigation, HALO, evaluated hyaluronic acid injectable treatments across the face in adults taking stable doses of GLP-1 medications. The Phase 4 study is examining patient satisfaction, skin quality, psychological outcomes and perceptions of natural appearance. The interim analysis presented at ASDS 2026 included 25 adults from the 75 participants treated. Results showed a 39.6-point mean improvement in FACE-Q Satisfaction With Facial Appearance at three months compared with baseline. Patient satisfaction findings were also notable, with 95.7% of participants reporting that they were satisfied or very satisfied that they still looked like themselves following treatment. Furthermore, 82.6% were satisfied or very satisfied with how natural their appearance looked, while 88% reported satisfaction with the natural appearance of their skin. These outcomes were measured using validated assessment tools, including FACE-Q and SKIN-Q. Most treatment-related adverse events reported during the interim analysis were mild and nonserious. The findings provide preliminary evidence about patient perceptions following HA injectable treatment in individuals experiencing facial changes associated with medical weight loss.
Advertisement
Allergan Expands Research in Aesthetic Medicine
The latest findings form part of Allergan Aesthetics’ broader clinical research program investigating aesthetic treatment approaches, skin quality and patient satisfaction. The company also presented additional research at ASDS 2026 covering multimodal facial and neck treatments, neurotoxin innovation and skincare approaches. The broader HARMONY IN DIVERSITY study included 130 participants across 10 clinical sites in the United States, with its first cohort evaluating multimodal treatment in 100 adults representing different age groups and Fitzpatrick skin types. The research program also included exploratory investigations of trenibotulinumtoxinE, an investigational neurotoxin, and BOTOX Cosmetic (onabotulinumtoxinA). According to Allergan Aesthetics, the objective is to generate clinical evidence that helps healthcare professionals understand changing aesthetic needs and make informed treatment decisions. Importantly, both GLP-1-related studies were prospective, multicenter, open-label and single-arm investigations without a comparison group. Therefore, the findings should be interpreted as patient-reported improvements rather than definitive evidence of comparative treatment effectiveness. Overall, the HARMONY IN DIVERSITY and HALO results represent an important development in aesthetic clinical research, highlighting the potential role of individualized, multimodal treatments for adults experiencing facial changes during medical weight loss.
Source: Allergan Aesthetics press release
